drugset / Trial / NCT00253266

Venlafaxine Augmentation in Treatment Resistant Depression

NCT00253266

Phase 4 Completed 126 enrolled Max-Planck-Institute of Psychiatry
RandomizedParallel-groupTriple-blindTreatment

Summary

This is an assessment of the efficacy of venlafaxine-HCL augmentation with the neuroleptic quetiapine in treatment resistant depression.

Timeline

Start
2008-04
Primary completion
2014-04
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 200 mg
Background Venlafaxine Small molecule 450 mg

Indications